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Abstract:
The chemotherapeutic use of doxorubicin (Dox) is hindered due to the development of irreversible cardiotoxicity. Specifically, childhood cancer survivors are at greater risk of Dox-induced cardiovascular complications. Because of the potent cardioprotective effect of phosphodiesterase 5 (PDE5) inhibitors, we examined the effect of long-acting PDE5
inhibitor, Tadalafil (Tada) against Dox-cardiotoxicity in juvenile mice. C57BL/6 mice (6 weeks old) were treated with Dox (20 mg/kg, IV) and/or Tada (10 mg/kg/daily for 14 days; PO). 
Introduction:
Childhood cancer survivors are about 325,000 in US, a quarter of them are older than thirty years old (Mariotto et al. 2009 ). Cardiopulmonary diseases are the third-leading cause of death in survivors of childhood cancer, after the recurrence of primary cancer and the development of second cancers (Mertens et al. 2001) . Chemotherapy induced cardiomyopathy is the first cause of cardiopulmonary problems among childhood cancer survivors, especially those treated with anthracycline (Lipshultz et al. 2013 ).
Anthracycline (family name for doxorubicin) are among the most effective antineoplastic drugs and it is still used in nearly 60% of childhood cancer patients (Ries et al. 1999) .
Anthracycline shows direct cardiotoxicity in molecular, cellular and clinical studies (Gianni et al. 2008) . Anthracycline-induced cardiotoxitity manifests as either early asymptomatic cardiac dysfunction or clinical heart failure due to dilated cardiomyopathy (Grenier and Lipshultz 1998) . The diastolic dysfunction is due to calcium spark and/or D r a f t and/or endothelial cell function (Shi et al. 2011) . A number of protective strategies have been attempted to overcome Dox induced cardiotoxic effect, which include early detection to modify chemotherapeutic regimen and/or the use of protective agents.
However, none of the known cardio protective drugs have shown superiority (Kalam and Marwick 2013) .
Previous studies from our laboratory have shown that phosphodiesterase 5 (PDE5) inhibitors including sildenafil (Viagra) and Tadalafil (Cialis) attenuated cardiac dysfunction in Dox-induced cardiomyopathy in adult mice (Das et al. 2010; Das et al. 2005; Fisher et al. 2005; Fogli et al. 2004; Jin et al. 2013; Koka et al. 2010; Koka and Kukreja 2010; Kukreja et al. 2012) . It was shown that treatment with these drugs before Based on this background, we hypothesized that treatment with Tadalafil will prevent Dox-induced early LV diastolic dysfunction through alterations in the expression of cytoskeletal and contractile proteins in juvenile mice. Since the expression PDE5 is higher in the right ventricle (RV) than LV (Nagendran et al. 2007) Fig 3) . Interestingly, after 10 weeks of Dox treatment, E' was further reduced (7.2 mm/sec ± 2.6) as compared to controls (13.7 ±2.8 mm/sec) (n=10, p<0.001 control vs Dox treated). Accordingly E/E' ratio was increased in Doxtreated (81.2±9.7) versus the control mice (33.6 ± 9.7, n=10, p<0.005 , Fig 3) . Fig 3) .
Expression of PDE5, Cytoskeletal and Contractile Proteins
The baseline expression of desmin, SERCA2, and myosin light chain (MYL) was higher in LV than RV (n=3, p<0.05, Fig 4) . The baseline expression of myosin heavy chain β (MHCβ), PDE5 and vimentin was higher in RV as compared to LV (n=6, p<0.05, Fig 4) .
Following treatment with Dox, SERCA2 was down regulated in both LV and RV (n=3, was prevented in LV (n=3, p<0.05) while no effect on RV; SERCA2 loss was prevented in RV (n=3, p<0.05) but had no effect in LV (n=3, p>0.05) (Fig. 5 A, B) . Similarly, Tada prevented Vimentin increase in RV (n=6, p<0.001) but had no effect in LV (n=6, p>0.05) D r a f t (Fig. 6 A, B) . Finally the combination treatment had no effect on MYL or PDE5 expression in both the ventricles (n=3, p>0.05) (Fig. 7 A. B and 8 A, B) .
Discussion:
Almost 60% . Accordingly, E/E' is an accurate method to predict LV filling pressure (Nagueh et al. 2009 ). Thus in the present study, we used the ratio between early mitral inflow velocity and lateral mitral early tissue Doppler wave (E/E') for detection of diastolic dysfunction. It has been reported that Dox treated adult rats had significant reduction in radial strain as compared with control rats by 8 weeks of treatment (Migrino et al. 2008) . These authors reported decreased FS by 12 weeks of treatment whereas our results showed preserved FS up to 10 weeks post treatment with diastolic dysfunction.
These differences could be attributed to the treatment schedule of Dox and animal species
i.e., adult rats versus juvenile mice used in our current experiments.
In the present study, we observed baseline expression of PDE5 that was higher in RV as compared to LV (Fig. 8 ), but it did not increase following Dox treatment.
Previous studies have shown that PDE5 is up-regulated 2-to 6-fold in experimental mice and human heart disease (Nagendran et al. 2007) . Ventricular PDE5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice (Tsai and Kass 2009). Chronic inhibition of PDE5 prevented and reversed cardiac hypertrophy (Takimoto et al. 2005) . It has been
shown that PDE5 cytosolic cGMP hydrolytic activity increases from 22% in non-failing heart to 43% in the failing heart (Vandeput et al. 2009 ), which potentially increases its influence and pharmacologic impact from its subsequent inhibition. Failure of Dox to increase PDE5 expression in the current study could be due to the age of these mice.
Moreover, these hearts had not developed LV hypertrophy or advanced heart failure. Our results showed that MHCβ increased in RV (n=3, p<0.05) while it remained unchanged in LV following Dox treatment (Fig. 7) . Increase in MHCβ in RV could be either due to the direct effect of Dox or secondary to pulmonary hypertension. LV and RV in causing Dox-induced LV diastolic dysfunction. We propose that Tadalafil could be potentially an important drug in preventing Dox cardiomyopathy and improving cardiac dysfunction in survivors of childhood cancer.
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